Argos Therapeutics, Inc. And Novo Nordisk A/S Announce Agreement To Develop Treatment For Systemic Autoimmune Disorders; Argos To Receive Up To $69 Million

DURHAM, N.C. & COPENHAGEN, Denmark--(BUSINESS WIRE)--March 14, 2006--Immunotherapy pioneer Argos Therapeutics and global healthcare leader Novo Nordisk, announced today they have entered into an agreement under which Argos has licensed to Novo Nordisk antibody technology for research and development of a treatment for systemic immune disorders, including systemic lupus erythematosus (SLE).